Pioneering research projects at the 8th Life Science Pitch Day at the IZB
A total of sixteen teams presented their innovative ideas to almost 50 investors at the Munich start-up center.
On July 13, 2023, the Munich Innovation and Start-up Center for Biotechnology (IZB) organized the 8th Life Science Pitch Day in cooperation with High-Tech Gründerfonds (HTGF), Leaps by Bayer, and Boehringer Ingelheim, which brought together sixteen biotech start-ups and project teams and almost 50 renowned life science investors and decision-makers from the industry. First, Dr. Peter Hanns Zobel, Managing Director of the IZB, gave a glimpse into current developments at the Munich biotech hub and welcomed Ingo Klöckner, Head of Portfolio and Reporting at Leaps by Bayer, and Dr. Sebastian Kreuz, Executive Director at Boehringer Ingelheim Venture Fund. Dr. Frank Hensel, Principal and General Manager of HTGF, and Dr. Laura Pedroza, Investment Manager at HTGF, moderated the event. The presentations by the sixteen project teams covered a wide range of topics and included innovative research from ADCs to cell therapies.
Start-up-Teams am 8. Munich Life Science Pitch Day 2023: First row (f.l.t.r.): Christian Pangratz, Atriva Therapeutics; Manfred Groeppel, Mallia Therapeutics; Alexander Steinkasserer; Johannes Nissen-Meyer, Khumbu.ai; Kerstin Pion Tossi, Thermosome; Grzegorz Popowicz, Khumbu.ai; Second row: Stephan Stenglein, Atriva Therapeutics; Christoph Schäfer, CIS Biopharma; Andreas Ernst, Phialogics; Bastian Linder, Umlaut.Bio; Pierre Tangermann, PerioTrap; Jörn Weinser, KyDo; Christian Geraths, CIS Biopharma; Bernd Hoffmann, SRTD biotech; Robert Macsics, Smartbax; Diogo Feleciano, BoosterTX; Pascal Schweizer, Thermosome; Jonathan Chriqui, Somagenetix; Melya Hughes Crameri, Genevieve Therapeutics; Mario Bunse, CARTemis; Anthea Wirges; CARTemis; Thomas Theelen, Tcelltech; Bernd Hoffmann, SRTD.
IZB
As part of the panel discussion “Mapping the Course – Pharma Perspectives on Identifying Trends and Setting Strategic Directions”, Dr. Laura Lane, VP Venture Sciences Europe at Eli Lilly & Co, Ingo Klöckner, Head of Portfolio and Reporting at Leaps by BAYER, Dr. Joachim Vogt, Director, Search and Evaluation International at AbbVie, and Dr. Sebastian Kreuz, Executive Director at Boehringer Ingelheim Venture Fund, led a lively exchange on current trends in the life sciences industry.
“This year we again heard about a profusion of different topics: from new cancer therapies to active agents against hair loss, and new approaches to treating diabetes and Parkinson’s. I am always pleased to see the innovative approaches that start-ups are pursuing and thus shaping medicine of the future. The Pitch Day is simply a great event, for which I would like to sincerely thank our partners,” said Dr. Peter Hanns Zobel, Managing Director of the IZB.
“We are impressed about the high quality of the pitches presented by the founders this year. These start-ups have the potential to significantly shape the future and we are excited about the next developments,” added Dr. Frank Hensel, Principal HTGF.
“I have now taken part in the Life Science Pitch Day at the IZB for the third time and I am always impressed: Realy exciting biotech projects, a high density of investors and a fantastic network atmosphere,” explained Dr. Joachim Vogt, Director, Search and Evaluation International at AbbVie.
“The company presentations at the Life Science Pitch Day impressed us again this year. The founders’ creative ideas and innovative solutions prove once again that we can still expect a lot from them in the future,” commented Dr. Sebastian Kreuz, Executive Director at Boehringer Ingelheim Venture Fund.
The following project teams presented their innovative research at the 8th Munich Life Science Pitch Day in the Innovation and Start-Up Center for Biotechnology (IZB):
- Atriva Therapeutics, Christian Pangratz: When prevention fails: An effective host cell-targeted therapy for severe RNA virus infections.
- Booster Therapeutics, Dr. Marianne Mertens: An approach to removing damaged proteins from cells to combat the accumulation of harmful proteins that occurs in many diseases such as Parkinson’s.
- CARTemis Therapeutics, Dr. Anthea Wirges: Development of novel cancer immunotherapies for previously incurable cancers with the vision of making CAR-T cells available to patients worldwide.
- CIS Pharma, Christoph Schäfer: Specializing in developing next-generation ADCs and radioligands targeting high unmet needs.
- Genevieve, Dr. Melya Hughes Crameri: Developing an mRNA CRISPR platform for precision editing and general purpose applications.
- khumbu.ai, Dr. Johannes Nissen-Meyer: Dedicated to finding a cure for diabetes through the revolutionary power of modern AI.
- KyDo Therapeutics, Dr. Matthias Stein-Gerlach: Developing first-in-class, covalent, allosteric AKT inhibitors as next-generation novel cancer therapies.
- Mallia Therapeutics, Prof. Dr. Steinkasserer: Developing a soluble CD83 molecule as a new therapeutic product for the topical treatment of hair loss.
- PerioTrap, Pierre Tangermann: The company’s goal is to transform oral health with oral microbiome modulators and sustainable therapy concepts.
- Phialogics, Dr. Andreas Ernst: Developing next-generation biologics to treat patients with acute and chronic autoimmune diseases.
- smartbax, Dr. Robert Macsics: Focuses on developing a new generation of antibiotics with novel dual mechanisms of action.
- Somagenetix, Dr. Andrin Oswald: Developing precision therapies for high mortality diseases in the fields of immunology, neurology, and metabolic diseases using its Phagocure platform.
- SRTD biotech, Dr. Bernd Hoffmann: Developing the first RNA-based platform technology for the use of selectively acting RNAs in various therapeutic areas.
- Tcelltech, Prof. Michael Platten: Developing a personalized, rapid, and cross-cancer T-cell therapy based on an AI bioinformatics tool for TCR identification and a non-viral vector for gene delivery.
- Thermosome, Dr. Pascal Schweizer: Novel tumor targeting approach enabling significantly increased local drug concentrations and better tumor penetration to improve clinical treatment efficacy.
- Umlaut.bio, Bastian Linder/ Lars Steinmetz: Focusing on small molecule drugs targeting tRNA modifications as novel therapeutics again
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
Something is happening in the life science industry ...
This is what true pioneering spirit looks like: Plenty of innovative start-ups are bringing fresh ideas, lifeblood and entrepreneurial spirit to change tomorrow's world for the better. Immerse yourself in the world of these young companies and take the opportunity to get in touch with the founders.
